Drugs / HLX15-SC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07477587 | May 2026 → May 2027 expected | plasma cell myeloma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-02-16 | Shanghai Henlius Biotech | Regulatory U.S. FDA Clears IND for Phase 1 Study of Henlius’ Subcutaneous Daratumumab Biosimilar henlius.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | Shanghai Henlius Biotech | First Patient Dosed in the U.S. for International Multi-center Phase 1 Clinical Trial of Henlius’ Subcutaneous Daratumumab Biosimilar HLX15-SC henlius.com ↗ |
| 2026-05-26 | Shanghai Henlius Biotech | Globalisation 2.0 | First Patient Dosed in China for International Multi-centre Phase 1 Clinical Trial of Henlius’ Subcutaneous Daratumumab Biosimilar HLX15-SC henlius.com ↗ |
| 2026-02-16 | Shanghai Henlius Biotech | U.S. FDA Clears IND for Phase 1 Study of Henlius’ Subcutaneous Daratumumab Biosimilar henlius.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX15-SC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07477587 ↗ |
| Route | Subcutaneous | “via SC administration” NCT07477587 ↗ |